All terms in DRUGBANK

Label Id Description
Sitamaquine DB04909 [Sitamaquine (WR-6026) is an orally active 8-aminoquinoline analog in development by the Walter Reed Army Institute, in collaboration with GlaxoSmithKline (formerly SmithKline Beecham), for the potential treatment of visceral leishmaniasis.]
Alfimeprase DB04919 [Alfimeprase is a recombinant analog of fibrolase. Fibrolase is a zinc-containing metalloproteinase isolated from the venom of the southern copperhead snake (<i>Agkistrodon contortrix contortrix</i>). It is a small protein that contains 203 residues (Randolph et al. 1992). Alfimeprase is being developed by Nuvelo.]
Ceftobiprole DB04918 [Ceftobiprole is an experimental cephalosporin antibiotic with activity against methicillin-resistant <i>Staphylococcus aureus</i>. It was discovered by Basilea Pharmaceutica and is being developed by Johnson &amp; Johnson Pharmaceutical Research and Development. Ceftobiprole is the first cephalosporin to demonstrate clinical efficacy in patients with infections due to methicillin-resistant staphylococci and, if approved by regulatory authorities, is expected to be a useful addition to the armamentarium of agents for the treatment of complicated skin infections and pneumonia.]
Renzapride DB04917 [Renzapride is currently in Phase III clinical development in the United States for the treatment of constipation-predominant irritable bowel syndrome (IBS-C). It has been suggested that renzapride is effective in the treatment of irritable bowel syndrome with alternating stool pattern. It is being developed by Alizyme of the UK.]
Idronoxil DB04915 [Idronoxil is a substance that is being studied in the treatment of cancer. It belongs to the family of drugs called signal transduction inhibitors.]
G17DT DB04914 [G17DT is a vaccine that neutralises gastrin-17, a hormone required for the growth of a number of cancers of the gastrointestinal tract. It is in phase III trials for advanced pancreatic cancer as a monotherapy and in combination with gemcitabine. It is also in a phase II/III trial for advanced stomach cancer in combination with 5-fluorouracil and cisplatin and in a late phase II trial for advanced colorectal cancer in combination with irinotecan.]
Stannsoporfin DB04912 [Stannsoporfin is a competitive heme oxygenase (HO) inhibitor being developed by InfaCare, a subsidiary of WellSpring Pharmaceuticals, for the prevention of hyperbilirubinemia in infants at risk of developing jaundice.]
Oritavancin DB04911 [Oritavancin (also known as LY333328) is a lipoglycopeptide antibacterial drug with effectiveness in treating infections caused by Gram-positive organisms.]
Oxibendazole DB04910 [Oxibendazole is a polymerase inhibitor in phase III trials for the treatment of helminth intestinal infections.]
DG031 DB04929 [DG031, deCODE genetics's lead compound, is being developed for the prevention of myocardial infarction, or heart attack.]
XP12B DB04928 [XP12B is being developed by Xanodyne Pharmaceuticals for the treatment of menorrhagia (heavy menstrual bleeding). It was granted Fast Track status for this indication by the FDA in November 2004.]
Neramexane DB04926 [Neramexane is a low-to-moderate affinity uncompetitive NMDA receptor antagonist.]
Desmoteplase DB04925 [Desmoteplase is a chemical in the saliva of vampire bats. It activates plasminogen to the serine protease, plasmin. Plasmin acts by breaking down fibrin blood clots. When a vampire bat bites its victim, it secretes an enzyme that prevents the blood from clotting. The enzyme is called DSPA (Desmodus rotundus salivary plasminogen activator) and scientists are using DSPA as stroke and heart attack medication. Desmoteplase is a recombinant form of vampire bat DSPA (Salivary plasminogen activator alpha 1).]
Itopride DB04924 [Itopride is a dopamine D2 antagonist with acetylcholinesterase inhibitory actions.]
rhThrombin DB04923 [rhThrombin (recombinant human thrombin) is being developed by ZymoGenetics, Inc. as a general aid to achieving hemostasis during surgery. ZymoGenetics is developing rhThrombin, a recombinant form of human thrombin that is not derived from animal or human blood, as an aid to controlling bleeding during surgery. Thrombin is used in more than 1 million surgeries each year in the United States. Currently, only thrombin derived from bovine blood is available in the U.S. as a stand-alone thrombin product. Bovine-derived thrombin has been associated with the development of antibodies that may cross-react with human blood proteins and in some cases these antibodies appear to be related to serious bleeding complications. The production of recombinant proteins is not dependent on the availability of blood from animals or human donors and can be scaled-up to meet market demand.]
Dirucotide DB04921 [Dirucotide is a synthetically prepared peptide. In particular, the sequence prepared is a 17 amino acid chain that is identical to a section of myelin basic protein (MBP) that is found in humans. Dirucotide has been developed for the treatment of multiple sclerosis (MS). Developed at the University of Alberta, dirucotide is being investigated by BioMS Medical Corp.]
Clevidipine DB04920 [Clevidipine is a dihydropyridine L-type calcium channel blocker that is selective for vascular smooth muscle and is indicated for blood pressure reduction when oral therapy is not an option.]
Flibanserin DB04908 [Flibanserin is the first drug to be approved for hypoactive sexual desire disorder (HSDD) in premenopausal women by the FDA in August 2015. It was originally developed as an antidepressant medication by Boehringer Ingelheim, but showed lack of efficacy in trials and was further developed as a hypoactive sexual disorder drug by Sprout Pharmaceuticals. Flibanserin's mechanism of action is attributed to its high affinity for 5-HTA1 and 5-HTA2 receptors, displaying agonist activity on 5-HTA1 and antagonist on 5-HTA2, resulting in lowering of serotonin in the brain as well as an effect on increasing norepinephrine and dopamine neurotransmitters.]
Sitimagene ceradenovec DB04907 [Sitimagene ceradenovec is a novel gene-based product for the treatment of patients with operable high grade glioma, a type of malignant brain tumour, given in addition to standard surgery and radiotherapy/chemotherapy. It is being developed by Ark Therapeutics.]
Tesmilifene DB04905 [Tesmilifene is a novel potentiator of chemotherapy which, when added to doxorubicin, achieved an unexpected and very large survival advantage over doxorubicin alone in a randomized trial in advanced breast cancer.]